Skip to main content
OpenTrials
Completed

NCT Number: NCT06068010

UVA Protection Factors of SPF 50 and 50+ Face Sunscreens

The goal of this observational study is to use the International Organization for Standardization (ISO) 24442:2011 in vivo method for assessment of the Ultraviolet A Protection Factor (UVAPF) of topical sunscreen products in healthy adults. The main question it aims to answer is to determine the degree of UVA-protection against UVA radiation.

An area of each subject's skin is exposed to UVA light without any protection and another (different) area is exposed after application of the sunscreen product under test. One further area is exposed after application of a reference UVA sunscreen formulation (S2), which is used to validate the procedure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ultraviolet-Induced Change in Normal Skin

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Allergisa, Campinas, Brazil

Loading trial locations.

About this study

The objective of the study conducted in accordance with the Declaration of Helsinki and national regulations regarding human studies is to evaluate the UVA protection factor of the investigational products against UVA, according to the ISO 24442:2011 methodology comparatively to a standard product (Standard S2) in healthy adult subjects.

Standard reference S2 sunscreen formula is used in a study if any test sample has an expected UVAPF of 12 or above. The mean UVAPF for the reference sample S2 is 12,7. The test result of the reference S2 UVAPF must be between 10,7 and 14,7 or the test is invalid and shall be repeated. The reference S2 may be used to validate any product test.

In order to determine the number of subjects, the 95 % confidence interval (CI) shall be taken into account. The 95 % confidence interval should lie within ±17 % of the mean UVAPF, and a minimum of 10 subjects is required.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fitzpatrick skin phototype: II, III or IV
  • colorimetric Individual Typology Angle (ITA°): 20° to 41°
  • intact skin on test site

Exclusion criteria

  • pregnant or lactating women
  • subjects using medication with photo-sensitizing potential
  • subjects receiving chemotherapy or radiotherapy
  • subjects who have had UV exposure on the back area in the four weeks prior to UVAPF testing

Treatment and study plan

Primary outcomes

  1. Evaluate the protection factor of the investigational product against UVA

    Time frame: from baseline to 24 hours

    The UVAPF test method uses persistent pigment darkening (PPD) responses of the skin as the end point for evaluating transmitted UVA radiation. The test is restricted to the area of the back of selected human subjects. An area of each subject's skin is exposed to UVA light without any protection and another (different) area is exposed after application of the sunscreen product under test. One further area is exposed after application of a reference UVA sunscreen formulation (S2), which is used to validate the procedure.

    To determine the UVAPF, incremental series of UVA exposures are delivered to five or six small sub-sites on the skin to induce darkening responses. These responses are visually assessed for pigment darkness 2 h to 24 h after UVA exposure, by the judgement of a trained evaluator.

Sponsors and collaborators

Lead sponsor

Cosmetique Active International

Industry

Registry information

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Oct 5, 2023
Registry last updated
Oct 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.